

## SGLT2 INHIBITORS PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)  Date:					Provider Information (required) Provider Name:			
Patient Name:				Specialty:		NPI:	NDI-	
Date of Birth:		Sex: □Male □Female		Office P	Office Phone:		Office Fax:	
Street Address:				Office Street Address:				
City:		State:	Zip:	City:		State:	Zip:	
Patient ID: R	1 1	l I I	1 1	Physicia	ın Signature:		•	
PHYSICIAN COMPLETES								
For Standard Option patients Farxiga, Glyxambi, Jardiance, Qtern, Synjardy/Synjardy XR, and Xigduo XR are preferred products.  Standard Option patients who switch to a preferred product can receive up to 2 fills without a copay in the benefit year.								
NOTE: Form must be completed in its entirety for processing								
Please select medication:								
□Invokamet 5		□Invokamet 2	XR 50/500mg		□Brenzavvy	□Stegl	atro	
□Invokamet 50/1000mg		□Invokamet XR 50/1000mg		g	□Invokana 100mg	□Stegl		
□Invokamet 150/500mg		☐Invokamet XR 150/500mg		g	□Invokana 300mg			
□Invokamet 150/1000mg		□Invokamet XR 150/1000m		ng	□Segluromet			
<ul> <li>Standard Option Patient: Would you like to participate in this program and switch the patient to a preferred medication: Farxiga, Glyxambi, Jardiance, Qtern, Synjardy, Synjardy XR, or Xigduo XR? Please select answer below:</li></ul>								
□No: Is there a clinical reason for not trying a preferred medication? □Yes* □No *If YES, please specify:								
2. Is this medication being used <i>exclusively</i> for weight loss? □Yes □No								
3. Does the patient have a diagnosis of type 2 diabetes mellitus (DM)? □Yes □No								
4. Invokana 100	mg Request: Does	the patient have a	urinary albumi	n (microa	lbumin) level greater tha	an 300mg per da	y? □Yes □No	
5. What is the patient's eGFR? mL/min/1.73m <sup>2</sup>								
6. Is the patient being treated for diabetic ketoacidosis (DKA), whose symptoms include nausea and/or vomiting, difficulty breathing, fruity odor on breath, and confusion which can require immediate medical attention? □Yes □No								

PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL QUESTIONS

PAGE 1 of 2



## **SGLT2 INHIBITORS**

**Prior Approval** P.O. Box 52080 MC 139 Federal Employee Program. PRIOR APPROVAL REQUEST Phoenix, AZ 85072-2080

**Attn. Clinical Services** Fax: 1-877-378-4727

Send completed form to:

Service Benefit Plan

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

PAGE 2 – PHYSICIAN COMPLETES					
Patient Name:	DOB:	Patient ID: R			
7. Will this medication be used in combin *If YES, please specify:					
*SGLT2 Inhibitors: Brenzavvy, Farx Steglatro, Steglujan, Synjardy/Synjar		kamet/Invokamet XR, Invokana, Jardiano XR	ce, Qtern, Segluromet,		
8. Has the patient been on this medication  □NO – this is INITIATION of thera a. Does the patient have an intoler metformin? □Yes □No	apy, please answer the follo				
	l peptidase 4 inhibitors (DP	r have they had an inadequate treatmer PP-4), glucagon-like peptide-1 recepto			
c. Does the patient have a HgbA10  "YES – this is a PA renewal for CO  a. Has the patient's condition improved the condition in the condi	NTINUATION of therapy	y, please answer the following question	n:		

PAGE 2 of 2



## SGLT2 INHIBITORS PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls.  Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA.</b>
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service.  The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed.  Please only fax the completed form once as duplicate submissions may delay processing times.

faster...
easier...
better...

CVS/caremark.
Introducing ePA! Online Prior
Authorizations in minutes through
Caremark.com/ePA. Sign up today!